Virginia Retirement Systems ET AL Acquires 19,400 Shares of Edwards Lifesciences Corp (NYSE:EW)

Virginia Retirement Systems ET AL grew its position in Edwards Lifesciences Corp (NYSE:EW) by 59.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 52,300 shares of the medical research company’s stock after buying an additional 19,400 shares during the period. Virginia Retirement Systems ET AL’s holdings in Edwards Lifesciences were worth $11,501,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Nuveen Asset Management LLC grew its position in Edwards Lifesciences by 8,278.5% during the second quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after buying an additional 3,904,405 shares in the last quarter. Bessemer Group Inc. lifted its stake in Edwards Lifesciences by 56,300.0% during the second quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock worth $93,045,000 after purchasing an additional 502,759 shares during the last quarter. Marshall Wace North America L.P. lifted its stake in Edwards Lifesciences by 394.9% during the second quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock worth $67,336,000 after purchasing an additional 290,838 shares during the last quarter. Jennison Associates LLC lifted its stake in Edwards Lifesciences by 4.8% during the second quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock worth $1,115,646,000 after purchasing an additional 275,182 shares during the last quarter. Finally, Thoroughbred Financial Services LLC lifted its stake in Edwards Lifesciences by 20,429.8% during the second quarter. Thoroughbred Financial Services LLC now owns 267,503 shares of the medical research company’s stock worth $26,750,000 after purchasing an additional 266,200 shares during the last quarter. 81.75% of the stock is owned by institutional investors.

Edwards Lifesciences stock traded up $3.38 during trading hours on Wednesday, reaching $225.47. 498,776 shares of the company’s stock were exchanged, compared to its average volume of 1,146,102. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18. The firm’s 50 day simple moving average is $222.13 and its 200 day simple moving average is $199.35. Edwards Lifesciences Corp has a twelve month low of $136.44 and a twelve month high of $231.26. The firm has a market capitalization of $47.25 billion, a PE ratio of 47.97, a PEG ratio of 2.86 and a beta of 0.84.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the business posted $1.24 EPS. The business’s revenue was up 15.2% compared to the same quarter last year. Analysts anticipate that Edwards Lifesciences Corp will post 5.33 EPS for the current year.

EW has been the subject of a number of research reports. ValuEngine cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. BTIG Research reaffirmed a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, July 25th. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 target price for the company in a research report on Thursday, July 25th. Morgan Stanley raised their target price on Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 24th. Finally, Citigroup set a $159.00 target price on Edwards Lifesciences and gave the stock a “sell” rating in a research report on Friday, July 26th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $223.22.

In other news, VP Catherine M. Szyman sold 372 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $214.53, for a total value of $79,805.16. Following the completion of the sale, the vice president now directly owns 18,010 shares in the company, valued at approximately $3,863,685.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 21,000 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $211.92, for a total value of $4,450,320.00. Following the completion of the sale, the vice president now owns 41,713 shares of the company’s stock, valued at $8,839,818.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 154,670 shares of company stock valued at $33,420,945. Company insiders own 1.63% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Why Invest in High-Yield Dividend Stocks?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.